Acute Myeloid Leukemia (AML) treatment has seen remarkable progress over the past 18 years, with 12 drug approvals including IDH and FLT3 inhibitors, and the transformative venetoclax and azacitidine combination therapy. This surge of innovation contrasts sharply with the decades of stagnation in AM
The EGFR MET bispecific agent Rybrevant (Amivantamab) shows clear activity in EGFR-mutated lung cancer, but its significant toxicity profile has led to clinician hesitation for its frontline use. Despite demonstrating a survival benefit in the frontline MARIPOSA trial, experts note that its adoption
Experts anticipate that future combination therapies for ATTR-CM, including emerging monoclonal antibody-based clearance medicines, will require rigorous clinical trials to determine optimal patient selection. Given the high cost of current ATTR-CM treatments, these trials are essential to identify